AR073384A1 - Formulaciones galenicas de compuestos organicos que comprenden alisquireno y amlodipina, y metodo de preparacion - Google Patents
Formulaciones galenicas de compuestos organicos que comprenden alisquireno y amlodipina, y metodo de preparacionInfo
- Publication number
- AR073384A1 AR073384A1 ARP090103591A ARP090103591A AR073384A1 AR 073384 A1 AR073384 A1 AR 073384A1 AR P090103591 A ARP090103591 A AR P090103591A AR P090103591 A ARP090103591 A AR P090103591A AR 073384 A1 AR073384 A1 AR 073384A1
- Authority
- AR
- Argentina
- Prior art keywords
- percent
- minutes
- oral dose
- pharmaceutical combination
- alisquirene
- Prior art date
Links
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title abstract 2
- 229960000528 amlodipine Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 150000002894 organic compounds Chemical class 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 206010020772 Hypertension Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000005189 Embolism Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 abstract 1
- 208000021642 Muscular disease Diseases 0.000 abstract 1
- 201000009623 Myopathy Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 210000004165 myocardium Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9894508P | 2008-09-22 | 2008-09-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073384A1 true AR073384A1 (es) | 2010-11-03 |
Family
ID=42040192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103591A AR073384A1 (es) | 2008-09-22 | 2009-09-18 | Formulaciones galenicas de compuestos organicos que comprenden alisquireno y amlodipina, y metodo de preparacion |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8613949B2 (enExample) |
| EP (1) | EP2328564A2 (enExample) |
| JP (2) | JP2012503020A (enExample) |
| KR (1) | KR20110060942A (enExample) |
| CN (1) | CN102159195A (enExample) |
| AR (1) | AR073384A1 (enExample) |
| AU (1) | AU2009292908B2 (enExample) |
| BR (1) | BRPI0919350A2 (enExample) |
| CA (1) | CA2736257A1 (enExample) |
| CL (1) | CL2011000594A1 (enExample) |
| CO (1) | CO6351711A2 (enExample) |
| EC (1) | ECSP11010999A (enExample) |
| IL (1) | IL211571A0 (enExample) |
| JO (1) | JO3239B1 (enExample) |
| MA (1) | MA32719B1 (enExample) |
| MX (1) | MX2011002988A (enExample) |
| MY (1) | MY153610A (enExample) |
| PE (1) | PE20110293A1 (enExample) |
| RU (2) | RU2011115712A (enExample) |
| TW (1) | TW201016217A (enExample) |
| WO (1) | WO2010033954A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2382969A1 (en) * | 2010-04-30 | 2011-11-02 | Sanovel Ilac Sanayi ve Ticaret A.S. | Multicoated Aliskiren formulations |
| CN102247344A (zh) * | 2011-05-30 | 2011-11-23 | 北京阜康仁生物制药科技有限公司 | 一种新型降血压组合物 |
| CN103070863A (zh) * | 2011-10-25 | 2013-05-01 | 河南省健康伟业生物医药研究股份有限公司 | 阿利吉仑和氨氯地平/左旋氨氯地平的口服固体制剂的制备新工艺 |
| US20180338922A1 (en) * | 2017-05-26 | 2018-11-29 | Esperion Therapeutics, Inc. | Fixed dose formulations |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003032954A1 (en) | 2001-10-17 | 2003-04-24 | Dr. Reddy's Laboratories Ltd. | Stabilized pharmaceutical formulations containing amlodipine maleate |
| HU226642B1 (en) | 2001-12-17 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Amlodipine bezylate tablets having extended stability and process for producing the same |
| KR20100137026A (ko) * | 2002-05-17 | 2010-12-29 | 노파르티스 아게 | 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는 약제학적 조성물 |
| DE10223282B3 (de) | 2002-05-24 | 2004-02-05 | Orga Kartensysteme Gmbh | Verfahren, Computerprogramm und Computersystem für einen prepaid Telekommunikationsdienst |
| FR2853904B1 (fr) | 2003-04-15 | 2007-11-16 | Air Liquide | Procede de production de liquides hydrocarbones mettant en oeuvre un procede fischer-tropsch |
| RU2426532C2 (ru) * | 2004-03-17 | 2011-08-20 | Новартис Аг | Применение органических соединений |
| MY144477A (en) * | 2004-03-17 | 2011-09-30 | Novartis Ag | Galenic formulations of organic compounds |
| PL1814527T5 (pl) * | 2004-11-05 | 2021-08-02 | Boehringer Ingelheim International Gmbh | Dwuwarstwowa tabletka zawierająca telmisartan i amlodypinę |
| WO2006059217A1 (en) | 2004-12-01 | 2006-06-08 | Ranbaxy Laboratories Limited | Stable solid dosage forms of amlodipine besylate and processes for their preparation |
| US20060116435A1 (en) * | 2004-12-01 | 2006-06-01 | Housel Tyler L | High strength polyurethane foam |
| GT200600371A (es) * | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
| PE20120542A1 (es) * | 2006-06-27 | 2012-05-14 | Novartis Ag | Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas |
| US20080161320A1 (en) | 2006-09-11 | 2008-07-03 | Xiong Cai | Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety |
| US8119841B2 (en) * | 2006-11-07 | 2012-02-21 | Novartis Ag | Crystalline forms of aliskiren hemifumarate |
-
2009
- 2009-09-17 JO JOP/2009/0348A patent/JO3239B1/ar active
- 2009-09-18 AR ARP090103591A patent/AR073384A1/es unknown
- 2009-09-21 TW TW098131810A patent/TW201016217A/zh unknown
- 2009-09-22 JP JP2011528052A patent/JP2012503020A/ja not_active Withdrawn
- 2009-09-22 US US13/063,955 patent/US8613949B2/en not_active Expired - Fee Related
- 2009-09-22 KR KR1020117009088A patent/KR20110060942A/ko not_active Withdrawn
- 2009-09-22 PE PE2011000647A patent/PE20110293A1/es not_active Application Discontinuation
- 2009-09-22 WO PCT/US2009/057750 patent/WO2010033954A2/en not_active Ceased
- 2009-09-22 RU RU2011115712/15A patent/RU2011115712A/ru unknown
- 2009-09-22 CA CA2736257A patent/CA2736257A1/en not_active Abandoned
- 2009-09-22 EP EP09736332A patent/EP2328564A2/en not_active Withdrawn
- 2009-09-22 MX MX2011002988A patent/MX2011002988A/es active IP Right Grant
- 2009-09-22 CN CN2009801369580A patent/CN102159195A/zh active Pending
- 2009-09-22 RU RU2014140552/15A patent/RU2014140552A/ru not_active Application Discontinuation
- 2009-09-22 AU AU2009292908A patent/AU2009292908B2/en not_active Ceased
- 2009-09-22 BR BRPI0919350A patent/BRPI0919350A2/pt not_active IP Right Cessation
- 2009-09-22 MY MYPI2011000931A patent/MY153610A/en unknown
-
2011
- 2011-03-03 IL IL211571A patent/IL211571A0/en unknown
- 2011-03-21 CL CL2011000594A patent/CL2011000594A1/es unknown
- 2011-03-25 CO CO11036957A patent/CO6351711A2/es not_active Application Discontinuation
- 2011-04-15 MA MA33780A patent/MA32719B1/fr unknown
- 2011-04-21 EC EC2011010999A patent/ECSP11010999A/es unknown
-
2014
- 2014-12-12 JP JP2014252210A patent/JP2015091830A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015091830A (ja) | 2015-05-14 |
| RU2014140552A (ru) | 2015-06-20 |
| TW201016217A (en) | 2010-05-01 |
| IL211571A0 (en) | 2011-05-31 |
| RU2011115712A (ru) | 2012-10-27 |
| WO2010033954A2 (en) | 2010-03-25 |
| US20110165240A1 (en) | 2011-07-07 |
| BRPI0919350A2 (pt) | 2015-12-29 |
| US8613949B2 (en) | 2013-12-24 |
| JO3239B1 (ar) | 2018-03-08 |
| JP2012503020A (ja) | 2012-02-02 |
| CO6351711A2 (es) | 2011-12-20 |
| CN102159195A (zh) | 2011-08-17 |
| AU2009292908A1 (en) | 2010-03-25 |
| CL2011000594A1 (es) | 2011-08-05 |
| WO2010033954A3 (en) | 2010-10-21 |
| MY153610A (en) | 2015-02-27 |
| MX2011002988A (es) | 2011-04-11 |
| AU2009292908B2 (en) | 2012-07-26 |
| CA2736257A1 (en) | 2010-03-25 |
| EP2328564A2 (en) | 2011-06-08 |
| MA32719B1 (fr) | 2011-10-02 |
| ECSP11010999A (es) | 2011-06-30 |
| KR20110060942A (ko) | 2011-06-08 |
| PE20110293A1 (es) | 2011-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066168A1 (es) | Formulaciones galenicas de compuestos organicos | |
| AR079552A1 (es) | Metodo para el tratamiento de la fibrilacion atrial. formulacion farmaceutica | |
| ECSP11011030A (es) | Método para tratar o prevenir la trombosis usando etexilato de dabigatrán o una sal del mismo con un perfil de seguridad mejorado sobre la terapia con warfarina convencional. | |
| BRPI0512193B8 (pt) | composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal | |
| EP4342540A3 (en) | Substituted heterocyclyl derivatives as cdk inhibitors | |
| NZ593622A (en) | Galenic formulations of organic compounds | |
| AR075423A1 (es) | Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos | |
| CO6382133A2 (es) | Metodo para tratar o prevenir la trombosis usando etexilato de dabigatran o una sal del mismo con una eficacia mejorada sobre la terapia con warfarina convencional | |
| BR112014009910A2 (pt) | formulações de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico | |
| AR048588A1 (es) | Uso de inhibidores de la fosfodiesterasa de tipo iii (pde iii) para la reduccion del tamano del corazon en mamiferos que padecen insuficiencia cardiaca | |
| GT201200164A (es) | "nuevos compuestos de espiropiperidina" | |
| AR020287A1 (es) | Preparaciones de una combinacion farmaceutica. | |
| PE20141049A1 (es) | Composicion farmaceutica antihipertensiva | |
| PE20081106A1 (es) | Comprimidos pediatricos de capecitabina | |
| AR063095A1 (es) | Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina | |
| CL2011000805A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular. | |
| AR072954A1 (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona, producto de fabricacion y envase | |
| EA201200037A1 (ru) | Терапевтические комбинации никотиновой кислоты и мелдония | |
| AR073651A1 (es) | Formulaciones galenicas de compuestos organicos | |
| AR068539A1 (es) | Formulaciones galenicas de compuestos organicos | |
| CR20110674A (es) | Otamixaban para el tratamiento de pacientes con alteración renal y de edad avanzada con infarto de miocardio sin elevación del ST | |
| AR075880A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno y valsartan. uso. metodo. | |
| PE20110293A1 (es) | Combinacion de dosis fija en la forma de una tableta de una sola capa que comprende alisquireno y amlodipina | |
| BR112013027685A2 (pt) | composição oral líquida compreendendo divalproex sódico e processo de preparação do mesmo | |
| AR079661A1 (es) | Derivados de n-(4f-3-{1-[indol-3-carbonil]piperidin-4-il}bencil)acetamidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |